Posted by Michael Wonder on 18 Jan 2023
Avidity Biosciences granted FDA fast track designation for AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy
18 January 2023 - Avidity Biosciences today announced that the US FDA has granted fast track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy.
AOC 1020 is being studied in the Phase 1/2 FORTITUDE clinical trial in adults with facioscapulohumeral muscular dystrophy and is the company's second muscle targeting small interfering RNA antibody oligonucleotide conjugate in clinical development.
